Latest news with #SNDA
Washington Post
12-05-2025
- Business
- Washington Post
Sonida Senior Living: Q1 Earnings Snapshot
DALLAS — DALLAS — Sonida Senior Living, Inc. (SNDA) on Monday reported a loss of $12.5 million in its first quarter. The Dallas-based company said it had a loss of 77 cents per share. The operator of senior living communities posted revenue of $91.9 million in the period. Its adjusted revenue was $80.3 million.
San Francisco Chronicle
12-05-2025
- Business
- San Francisco Chronicle
Sonida Senior Living: Q1 Earnings Snapshot
DALLAS (AP) — DALLAS (AP) — Sonida Senior Living, Inc. (SNDA) on Monday reported a loss of $12.5 million in its first quarter. The Dallas-based company said it had a loss of 77 cents per share. The operator of senior living communities posted revenue of $91.9 million in the period. Its adjusted revenue was $80.3 million. _____
Yahoo
12-05-2025
- Business
- Yahoo
Sonida Senior Living: Q1 Earnings Snapshot
DALLAS (AP) — DALLAS (AP) — Sonida Senior Living, Inc. (SNDA) on Monday reported a loss of $12.5 million in its first quarter. The Dallas-based company said it had a loss of 77 cents per share. The operator of senior living communities posted revenue of $91.9 million in the period. Its adjusted revenue was $80.3 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on SNDA at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-05-2025
- Business
- Yahoo
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Revvvi Forge Net Revenue: $20 million in the first full quarter of the launch. Nick Timbo Net Revenue: $13.6 million from the first two months of the joint launch with Insight. Total Combined Net Sales: $34 million from Revvvi Forge and Nick Timbo. Cash and Equivalents: $602.1 million as of March 31st. Collaboration Loss: $200,000 share of the net commercial loss for Nick Timbo. Managed Care Coverage: 72% of all managed care lives have formal coverage policies for Revvvi Forge. Infusions Administered: More than 1,250 infusions of Nick Timbo administered year-to-date. Top Accounts Ordering Nick Timbo: Approximately 95% of top accounts and more than 70% of all bone marrow transplant centers have ordered. Warning! GuruFocus has detected 5 Warning Signs with SNDX. Release Date: May 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) reported strong financial performance with $20 million in net revenue from Revvvi Forge and $13.6 million from Nick Timbo in the first quarter of 2025. The company has a robust pipeline with ongoing clinical trials, including the initiation of the Evolve II trial for Revvvi Forge, targeting a high unmet medical need in AML patients. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is well-funded with $602.1 million in cash and equivalents, supporting its strategic initiatives and potential market expansions. The company has achieved significant milestones, including the submission of a supplemental new drug application (SNDA) for Revvvi Forge, seeking priority review for the treatment of relapse or refractory mutant NPM1 AML. Strong market access and formulary coverage for Revvvi Forge, with approximately 72% of managed care lives covered, facilitating quick patient access to the medication. The company faces challenges in accurately estimating the total addressable market for its products, as the actual patient population may differ from initial projections. There is limited data on the long-term duration of therapy and refill dynamics for Revvvi Forge, making it difficult to predict future revenue streams accurately. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is still in the early stages of collecting real-world evidence for its products, which may impact the ability to provide detailed insights into patient outcomes and treatment patterns. The company has not yet provided specific details on the powering of its Evolve II trial, which could affect investor confidence in the trial's potential success. Reimbursement for post-transplant use of Revvvi Forge remains uncertain, which could impact the drug's adoption and revenue potential in this setting. Q: What are you seeing in regards to the repeat prescribers for Revvvi Forge? Are there certain centers with high repeat prescribers, or are they more spread out? A: Steven Closter, Chief Commercial Officer: About 80% of our tier one and tier two accounts have ordered more than once, either for another patient or for a refill. Usage is not concentrated only in these groups; we are seeing prescriptions from a wide range of centers, including smaller academic centers and community practices. The user base is growing, and those using the drug more than once are increasing. Q: For patients receiving Revvvi Forge, are you seeing a similar pace of patients receiving transplants as in clinical trials? Are any patients using Revvvi Forge as maintenance therapy? A: Michael Metzger, CEO: Currently, we have anecdotal information from physicians reporting that they are taking patients to transplant and expect them to go back on Revvvi Forge post-engraftment in the maintenance setting. It's early to comment extensively, but the initial feedback is encouraging. Q: Can you share any color on the month-over-month trends for new patient ads for Revvvi Forge in Q1? Was patient flow steady, or did you see acceleration? A: Steven Closter, Chief Commercial Officer: We are not providing specific numbers yet, but we are happy with the trends. There was a good ramp from Q4 into Q1, and we are moving into a steady state. We expect to see a clearer run rate after two full quarters. Q: Could you speak about any trends you are seeing in GVHD, particularly in any subgroups? A: Peter Ordentlich, Chief Scientific Officer: It's early for us to comment on specific trends in GVHD subgroups. We are collecting real-world evidence, but we only have partial quarter data so far. Q: Could you comment on the degree of off-label use in NPM1 patients contributing to Q1 sales? Also, how might the change in the design of the Evolve 2 study impact trial completion timing? A: Michael Metzger, CEO: The vast majority of Q1 sales are from on-label KMT2A patients. Regarding the Evolve 2 study, we are amending the analysis plan to include CR as a dual primary endpoint, which supports potential accelerated approval. This change does not impact the trial's timeline. Q: Can you provide additional color around the powering for the Evolve 2 trial in the unfit population? A: Michael Metzger, CEO: We haven't disclosed specific powering details, but the trial is powered based on the MPM1 population, which is larger than the KMT2A population. The trial includes both populations but focuses on MPM1 for efficacy analysis. Q: Why are you pursuing two separate trials for MPM1 and KMT2A in the fit studies, while they are combined in the unfit study? A: Michael Metzger, CEO: The decision is based on the differences between the patient populations. Separate trials allow us to tailor the design to achieve the best outcomes for each group. Q: Regarding the NCCN guidelines, do you think you could realistically get in front of them with your publication by their May 19th meeting? A: Michael Metzger, CEO: We are optimistic about submitting our manuscript to the guidelines quickly. While it's uncertain if it will be in time for the May 19th meeting, the committee may meet ad hoc for practice-changing medicines. We expect inclusion in the guidelines relatively soon. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
18-03-2025
- Business
- Yahoo
Sonida Senior Living Inc (SNDA) Q4 2024 Earnings Call Highlights: Impressive Growth and ...
Same-Store Adjusted Community NOI Growth: 19% year-over-year increase in 2024. Adjusted EBITDA Growth: 27% year-over-year increase in 2024. Occupancy Improvement: 180 basis points increase in same-store occupancy in 2024. RevPOR Growth: Nearly 6% year-over-year increase in 2024. Portfolio Expansion: 30% increase in total units with the integration of 20 owned and 3 managed communities. NOI Margin: 21.7% for Q4 2024 acquisition communities. Debt Transactions: $18.3 million discounted payoff on a $28.4 million loan and extension of $220 million debt maturity to January 2029. Same-Store Revenue Increase: Over $14 million annualized increase, driven by a 5.1% rate increase and 70 basis points occupancy growth. Pro Forma NOI Growth: 9.6% increase in Q4 2024, excluding non-recurring credits. Annual Revenue Growth: 7.5% increase from occupancy gain and RevPOR increase. Annual Adjusted Community NOI Increase: 21% or $11.4 million, excluding non-recurring state grants. Occupancy Rate: 86.6% weighted average in Q4 2024. Annual Rate Increase: 6.3% in 2024. Level of Care Revenue Increase: $1.1 million or 8.3% year-over-year increase. Labor Expense Trends: Average annual total employee count increased by 2.1%. Non-Labor Expense Reduction: Decreased 60 basis points as a percentage of revenue. Debt Composition: 61% fixed rate debt with a weighted average interest rate of 4.7%. NOI Growth Potential: Additional $9 million of NOI from Q4 2024 acquisitions, with potential for $22 million more. Warning! GuruFocus has detected 4 Warning Signs with SNDA. Release Date: March 17, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sonida Senior Living Inc (NYSE:SNDA) achieved significant year-over-year growth in same-store adjusted community NOI and adjusted EBITDA, with increases of 19% and 27%, respectively. The company successfully integrated 20 owned and three managed communities, representing a near 30% increase in total units to the portfolio. Sonida Senior Living Inc (NYSE:SNDA) executed six transactions totaling more than $250 million in gross asset value, enhancing its capital allocation strategy. Employee turnover decreased nearly 10% in 2024, reflecting successful investment in employee experience and retention strategies. The company reported a 15% year-over-year increase in lead volume and an 11% increase in tour volume, indicating strong demand and effective marketing strategies. Q4 2024 was the first quarter since the pandemic where Sonida Senior Living Inc (NYSE:SNDA) did not realize occupancy growth from the previous quarter, with a slight decline in occupancy. The company faced challenges with Medicaid-related aging in Indiana, leading to an increase in bad debt expense. Despite improvements, the company still relies on third-party sales referral partners, which could impact cost efficiency. Sonida Senior Living Inc (NYSE:SNDA) has a significant debt maturity of $113 million due in March 2027, which may require strategic financial planning. The company anticipates no significant one-time real estate tax credits in the future, which could impact financial performance compared to previous years. Q: Can you provide insights into the current pricing trends and labor costs, especially in light of your $100 million target? A: Brandon Ribar, President and CEO, explained that 2025 is expected to be a strong year for pricing, similar to 2024. With current occupancy levels, they anticipate continued pricing gains. For newly acquired communities, there is a focus on accelerating top-line recovery due to occupancy opportunities. Labor costs are being diligently managed, with no significant impacts from immigration changes, allowing for potential margin expansion. Q: What are the expectations for occupancy and revenue growth in 2025? A: Brandon Ribar noted that early Q1 trends indicate continued year-over-year growth in occupancy and strong rate improvement. The goal is to achieve same-store NOI growth at the high end of their peer group, benefiting from higher incremental flow-through as more communities reach stabilized operating levels. Q: How is Sonida addressing employee turnover and labor challenges? A: Brandon Ribar highlighted that employee turnover decreased nearly 10% in 2024 due to increased investment in employee experience, including success-based wages and benefits, and a robust recognition and development program. The company is focused on further optimizing labor mix by reducing premium labor. Q: Can you elaborate on the recent debt transactions and their impact on the company's financial position? A: Kevin Detz, CFO, detailed two significant debt transactions in Q4 2024: a discounted payoff of $18.3 million on a $28.4 million loan and an extension of maturities for 18 communities with Fannie Mae. These transactions provide financial flexibility, with the next significant debt maturity in March 2027. Q: What are the strategic priorities for capital allocation and acquisitions in 2025? A: Brandon Ribar emphasized the focus on executing individual community business plans and leveraging Sonida's operating capabilities and capital availability. The company aims to capitalize on a robust acquisition pipeline, targeting high-quality underperforming or mispriced assets for accretive returns. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
